Sphingosine kinase-1/sphingosine 1-phosphate pathway in diabetic nephropathy

Chinese Medical Journal

Volumn 127, Issue 16, 2014, Pages 3004-3010

  Deng, Yan Hui ^a   Lan, Tian ^b   Huang, Juan ^c   Huang, He Qing ^c  

^a THE THIRD AFFILIATED HOSPITAL OF SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGDONG PHARMACEUTICAL UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Extracellular matrix; Fibrosis; Sphingosine 1 phosphate; Sphingosine kinase 1; Transforming growth factor

Indexed keywords

LYSOPHOSPHOLIPID; PHOSPHOTRANSFERASE; SPHINGOSINE; SPHINGOSINE 1-PHOSPHATE; SPHINGOSINE KINASE;

ANALOGS AND DERIVATIVES; DIABETIC NEPHROPATHY; ENZYMOLOGY; EXTRACELLULAR MATRIX; HUMAN; METABOLISM; SIGNAL TRANSDUCTION;

DIABETIC NEPHROPATHIES; EXTRACELLULAR MATRIX; HUMANS; LYSOPHOSPHOLIPIDS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); SIGNAL TRANSDUCTION; SPHINGOSINE;

EID: 84906485346     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.20133344     Document Type: Review

References (84)

1. Shaw JE, Sicree RA, Zimmet PZ. Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res clin Pract 2010; 87: 4-14.
2. Molitch ME, DeFronzo RA, Franz MJ, Keane WF, Mogensen CE, Parving HH, et al. Nephropathy in diabetes. Diabetes Care 2004; 27: S79-S83.
3. Schena FP, Gesualdo L. Pathogenetic mechanisms of diabetic nephropathy. J Am Soc Nephrol 2005; 16: S30-S33.
4. Ichinose K, Kawasaki E, Eguchi K. Recent advancement of understanding pathogenesis of type 1 diabetes and potential relevance to diabetic nephropathy. Am J Nephrol 2007; 27: 554-564.
5. Adler S. Structure-function relationships associated with extracellular matrix alterations in diabetic glomerulopathy. J Am Soc Nephrol 1994; 5: 1165-1172.
6. Abdel Wahab N, Mason RM. Connective tissue growth factor and renal diseases: some answers, more questions. Curr Opin Nephrol Hypertens 2004; 13: 53-58.
7. Zhao LS, Bai WW, Xiang GD, Yue L, Sun HL. Clinical evaluation of valsartan and metoprolol tartrate in treatment of diabetic nephropathy with positive β1-adrenergic and antiangiotensin II type 1 receptor antibody. Chin Med J 2012; 125: 3543-3547.
8. Shen WF. Optimizing prevention of contrast-induced acute kidney injury in type 2 diabetic patients with at least moderate renal impairment. Chin Med J 2012; 125: 3365-3367.
9. Geng W, Fu XH, Gu XS, Wang YB, Wang XC, Li W, et al. Preventive effects of anisodamine against contrast-induced nephropathy in type 2 diabetics with renal insufficiency undergoing coronary angiography or angioplasty. Chin Med J 2012; 125: 3368-3372.
10. de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA 2011; 305: 2532-2539.
11. Bonegio R, Susztak K. Notch signaling in diabetic nephropathy. Exp Cell Res 2012; 318: 986-992.
12. Hannun YA, Obeid LM. Mechanisms of ceramide-mediated apoptosis. Adv Exp Med Biol 1997; 407: 145-149.
13. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003; 4: 397-407.
14. Hannun YA, Obeid LM. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat Rev Mol Cell Biol 2008; 9: 139-150.
15. Takabe K, Paugh SW, Milstien S, Spiegel S. "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 2008; 60: 181-195.
16. Alemany R, van Koppen CJ, Danneberg K, Ter Braak M, Meyer Zu Heringdorf D. Regulation and functional roles of sphingosine kinases. Naunyn Schmiedebergs Arch Pharmacol 2007; 374: 413-428.
17. Hait NC, Oskeritzian CA, Paugh SW, Milstien S, Spiegel S. Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochimi Biophys Acta 2006; 1758: 2016-2026.
18. Perez GI, Knudson CM, Leykin L, Korsmeyer SJ, Tilly JL. Apoptosis-associated signaling pathways are required for chemotherapy-mediated female germ cell destruction. Nat Med 1997; 3: 1228-1232.
19. Xia P, Wang L, Gamble JR, Vadas MA. Activation of sphingosine kinase by tumor necrosis factor-alpha inhibits apoptosis in human endothelial cells. J Biol Chem 1999; 274: 34499-34505.
20. Morita Y, Perez GI, Paris F, Miranda SR, Ehleiter D, Haimovitz-Friedman A, et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1- phosphate therapy. Nat Med 2000; 6: 1109-1114.
21. Olivera A, Kohama T, Tu Z, Milstien S, Spiegel S. Purification and characterization of rat kidney sphingosine kinase. J Biol Chem 1998; 273: 12576-12583.
22. Hinkovska-Galcheva V, VanWay SM, Shanley TP, Kunkel RG. The role of sphingosine-1- phosphate and ceramide-1-phosphate in calcium homeostasis. Curr Opin Investig Drugs 2008; 9: 1192-1205.
23. Karliner JS. Sphingosine kinase and sphingosine 1-phosphate in cardioprotection. J cardiovasc Pharmacol 2009; 53: 189-197.
24. Hait NC, Allegood J, Maceyka M, Strub GM, Harikumar KB, Singh SK, et al. Regulation of histone acetylation in the nucleus by sphingosine-1-phosphate. Science 2009; 325: 1254-1257.
25. Don AS, Rosen H. A lipid binding domain in sphingosine kinase 2. Biochem Biophys Res Commun 2009; 380: 87-92.
26. Pitson SM. Regulation of sphingosine kinase and sphingolipid signaling. Trends Biochem Sci 2011; 36: 97-107.
27. Venkataraman K, Thangada S, Michaud J, Oo ML, Ai Y, Lee YM, et al. Extracellular export of sphingosine kinase-1a contributes to the vascular S1P gradient. Biochem J 2006; 397: 461-471.
28. Wang L, Xing XP, Holmes A, Wadham C, Gamble JR, Vadas MA, et al. Activation of the sphingosine kinase-signaling pathway by high glucose mediates the proinflammatory phenotype of endothelial cells. Circ Res 2005; 97: 891-899.
29. You B, Ren A, Yan G, Sun J. Activation of sphingosine kinase-1 mediates inhibition of vascular smooth muscle cell apoptosis by hyperglycemia. Diabetes 2007; 56: 1445-1453.
30. Geoffroy K, Wiernsperger N, Lagarde M, El Bawab S. Bimodal effect of advanced glycation end products on mesangial cell proliferation is mediated by neutral ceramidase regulation and endogenous sphingolipids. J Biol Chem 2004; 279: 34343-34352.
31. Geoffroy K, Troncy L, Wiernsperger N, Lagarde M, El Bawab S. Glomerular proliferation during early stages of diabetic nephropathy is associated with local increase of sphingosine-1- phosphate levels. FEBS Lett 2005; 579: 1249-1254.
32. Pitson SM, Moretti PA, Zebol JR, Lynn HE, Xia P, Vadas MA, et al. Activation of sphingosine kinase 1 by ERK1/2-mediated phosphorylation. EMBO J 2003; 22: 5491-5500.
33. Liu Y, Wada R, Yamashita T, Mi Y, Deng CX, Hobson JP, et al. Edg-1, the G protein-coupled receptor for sphingosine-1-phosphate, is essential for vascular maturation. J Clin Invest 2000; 106: 951-961.
34. Ishii I, Ye X, Friedman B, Kawamura S, Contos JJ, Kingsbury MA, et al. Marked perinatal lethality and cellular signaling deficits in mice null for the two sphingosine 1-phosphate (S1P) receptors, S1P(2)/ LP(B2)/EDG-5 and S1P(3)/ LP(B3)/EDG-3. J Biol Chem 2002; 277: 25152-25159.
35. Wang W, Graeler MH, Goetzl EJ. Type 4 sphingosine 1-phosphate G protein-coupled receptor (S1P4) transduces S1P effects on T cell proliferation and cytokine secretion without signaling migration. FASEB J 2005; 19: 1731-1733.
36. Walzer T, Chiossone L, Chaix J, Calver A, Carozzo C, Garrigue-Antar L, et al. Natural killer cell trafficking in vivo requires a dedicated sphingosine 1-phosphate receptor. Nat Immunol 2007; 8: 1337-1344.
37. Camerer E, Regard JB, Cornelissen I, Srinivasan Y, Duong DN, Palmer D, et al. Sphingosine-1- phosphate in the plasma compartment regulates basal and inflammation- induced vascular leak in mice. J Clin Invest 2009; 119: 1871-1879.
38. Heo K, Park KA, Kim YH, Kim SH, Oh YS, Kim IH, et al. Sphingosine 1-phosphate induces vesicular endothelial growth factor expression in endothelial cells. BMB Rep 2009; 42: 685-690.
39. Kupperman E, An S, Osborne N, Waldron S, Stainier DY. A sphingosine-1-phosphate receptor regulates cell migration during vertebrate heart development. Nature 2000; 406: 192-195.
40. Rosen H, Goetzl EJ. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat Rev Immunol 2005; 5: 560-570.
41. Rivera J, Proia RL, Olivera A. The alliance of sphingosine-1- phosphate and its receptors in immunity. Nat Rev Immunol 2008; 8: 753-763.
42. Pitson SM, Moretti PA, Zebol JR, Xia P, Gamble JR, Vadas MA, et al. Expression of a catalytically inactive sphingosine kinase mutant blocks agonist-induced sphingosine kinase activation. A dominant-negative sphingosine kinase. J Biol Chem 2000; 275: 33945-33950.
43. Johnson KR, Becker KP, Facchinetti MM, Hannun YA, Obeid LM. PKC-dependent activation of sphingosine kinase 1 and translocation to the plasma membrane. Extracellular release of sphingosine-1-phosphate induced by phorbol 12-myristate 13-acetate (PMA). J Biol Chem 2002; 277: 35257-35262.
44. Pitson SM, Xia P, Leclercq TM, Moretti PA, Zebol JR, Lynn HE, et al. Phosphorylation-dependent translocation of sphingosine kinase to the plasma membrane drives its oncogenic signalling. J Exp Med 2005; 201: 49-54.
45. van Koppen CJ, Meyer zu Heringdorf D, Alemany R, Jakobs KH. Sphingosine kinase-mediated calcium signaling by muscarinic acetylcholine receptors. Life Sci 2001; 68: 2535-2540.
46. Taha TA, Osta W, Kozhaya L, Bielawski J, Johnson KR, Gillanders WE, et al. Down-regulation of sphingosine kinase-1 by DNA damage: dependence on proteases and p53. J Biol Chem 2004; 279: 20546-20554.
47. Taha TA, Kitatani K, Bielawski J, Cho W, Hannun YA, Obeid LM. Tumor necrosis factor induces the loss of sphingosine kinase-1 by a cathepsin B-dependent mechanism. J Biol Chem 2005; 280: 17196-17202.
48. Awad AS, Rouse MD, Khutsishvili K, Huang L, Bolton WK, Lynch KR, et al. Chronic sphingosine 1-phosphate 1 receptor activation attenuates early-stage diabetic nephropathy independent of lymphocytes. Kidney Int 2011; 79: 1090-1098.
49. Shu X, Wu W, Mosteller RD, Broek D. Sphingosine kinase mediates vascular endothelial growth factor-induced activation of ras and mitogen-activated protein kinases. Mol Cell Biol 2002; 22: 7758-7768.
50. El-Shewy HM, Johnson KR, Lee MH, Jaffa AA, Obeid LM, Luttrell LM. Insulin-like growth factors mediate heterotrimeric G protein-dependent ERK1/2 activation by transactivating sphingosine 1-phosphate receptors. J Biol Chem 2006; 281: 31399-31407.
51. Hammad SM, Crellin HG, Wu BX, Melton J, Anelli V, Obeid LM. Dual and distinct roles for sphingosine kinase 1 and sphingosine 1 phosphate in the response to inflammatory stimuli in RAW macrophages. Prostaglandins Other Lipid Mediat 2008; 85: 107-114.
52. Xia P, Gamble JR, Rye KA, Wang L, Hii CS, Cockerill P, et al. Tumor necrosis factor-alpha induces adhesion molecule expression through the sphingosine kinase pathway. Proc Natl Acad Sci USA 1998; 95: 14196-14201.
53. Billich A, Bornancin F, Mechtcheriakova D, Natt F, Huesken D, Baumruker T. Basal and induced sphingosine kinase 1 activity in A549 carcinoma cells: function in cell survival and IL-1beta and TNF-alpha induced production of inflammatory mediators. Cell Signal 2005; 17: 1203-1217.
54. Liu Y. Renal fibrosis: new insights into the pathogenesis and therapeutics. Kidney Int 2006; 69: 213-217.
55. Cove-Smith A, Hendry BM. The regulation of mesangial cell proliferation. Nephron Exp Nephrol 2008; 108: e74-e79.
56. Kirby RJ, Jin Y, Fu J, Cubillos J, Swertfeger D, Arend LJ. Dynamic regulation of sphingosine-1-phosphate homeostasis during development of mouse metanephric kidney. Am J Physiol Renal Physiol 2009; 296: F634-F641.
57. Katsuma S, Hada Y, Ueda T, Shiojima S, Hirasawa A, Tanoue A, et al. Signalling mechanisms in sphingosine 1-phosphate- promoted mesangial cell proliferation. Genes Cells 2002; 7: 1217-1230.
58. Klawitter S, Hofmann LP, Pfeilschifter J, Huwiler A. Extracellular nucleotides induce migration of renal mesangial cells by upregulating sphingosine kinase-1 expression and activity. Br J Pharmacol 2007; 150: 271-280.
59. Xin C, Ren S, Kleuser B, Shabahang S, Eberhardt W, Radeke H, et al. Sphingosine 1-phosphate cross-activates the Smad signaling cascade and mimics transforming growth factor-beta- induced cell responses. J Biol Chem 2004; 279: 35255-35262.
60. Katsuma S, Ruike Y, Yano T, Kimura M, Hirasawa A, Tsujimoto G. Transcriptional regulation of connective tissue growth factor by sphingosine 1-phosphate in rat cultured mesangial cells. FEBS Lett 2005; 579: 2576-2582.
61. El-Shewy HM, Sohn M, Wilson P, Lee MH, Hammad SM, Luttrell LM, et al. Low-density lipoprotein induced expression of connective tissue growth factor via transactivation of sphingosine 1-phosphate receptors in mesangial cells. Mol Endocrinol 2012; 26: 833-845.
62. Lan T, Liu W, Xie X, Xu S, Huang K, Peng J, et al. Sphingosine kinase-1 pathway mediates high glucose-induced fibronectin expression in glomerular mesangial cells. Mol Endocrinol 2011; 25: 2094-2105.
63. Perbal B. CCN proteins: multifunctional signalling regulators. Lancet 2004; 363: 62-64.
64. Wahab N, Cox D, Witherden A, Mason RM. Connective tissue growth factor (CTGF) promotes activated mesangial cell survival via up-regulation of mitogen-activated protein kinase phosphatase-1 (MKP-1). Biochem J 2007; 406: 131-138.
65. Hanafusa N, Yatomi Y, Yamada K, Hori Y, Nangaku M, Okuda T, et al. Sphingosine 1-phosphate stimulates rat mesangial cell proliferation from outside the cells. Nephrol Dial Transplant 2002; 17: 580-586.
66. Simonson MS. Phenotypic transitions and fibrosis in diabetic nephropathy. Kidney Int 2007; 71: 846-854.
67. Sharma K, Ziyadeh FN. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator. Diabetes 1995; 44: 1139-1146.
68. Summers SA. Sphingolipids and insulin resistance: the five Ws. Curr Opin Lipidol 2010; 21: 128-135.
69. Deevska GM, Nikolova-Karakashian MN. The twists and turns of sphingolipid pathway in glucose regulation. Biochimie 2011; 93: 32-38.
70. Lan T, Shen X, Liu P, Liu W, Xu S, Xie X, et al. Berberine ameliorates renal injury in diabetic C57BL/6 mice: involvement of suppression of SphK-S1P signaling pathway. Arch Biochem Biophys 2010; 502: 112-120.
71. Liu W, Lan T, Xie X, Huang K, Peng J, Huang J, et al. S1P2 receptor mediates sphingosine-1-phosphate-induced fibronectin expression via MAPK signaling pathway in mesangial cells under high glucose condition. Exp Cell Res 2012; 318: 936-943.
72. Imasawa T, Kitamura H, Ohkawa R, Satoh Y, Miyashita A, Yatomi Y. Unbalanced expression of sphingosine 1-phosphate receptors in diabetic nephropathy. Exp Toxicol Pathol 2010; 62: 53-60.
73. Tamura K, Nyui N, Tamura N, Fujita T, Kihara M, Toya Y, et al. Mechanism of angiotensin II-mediated regulation of fibronectin gene in rat vascular smooth muscle cells. J Biol Chem 1998; 273: 26487-26496.
74. Guo B, Koya D, Isono M, Sugimoto T, Kashiwagi A, Haneda M. Peroxisome proliferator- activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. Diabetes 2004; 53: 200-208.
75. Paugh BS, Bryan L, Paugh SW, Wilczynska KM, Alvarez SM, Singh SK, et al. Interleukin-1 regulates the expression of sphingosine kinase 1 in glioblastoma cells. J Biol Chem 2009; 284: 3408-3417.
76. Huang K, Huang J, Chen C, Hao J, Wang S, Huang J, et al. AP-1 regulates sphingosine kinase 1 expression in a positive feedback manner in glomerular mesangial cells exposed to high glucose. Cell Signal 2014; 26: 629-638.
77. Yamagishi S, Inagaki Y, Okamoto T, Amano S, Koga K, Takeuchi M, et al. Advanced glycation end product-induced apoptosis and overexpression of vascular endothelial growth factor and monocyte chemoattractant protein-1 in human- cultured mesangial cells. J Biol Chem 2002; 277: 20309-20315.
78. Fukami K, Ueda S, Yamagishi S, Kato S, Inagaki Y, Takeuchi M, et al. AGEs activate mesangial TGF-beta-Smad signaling via an angiotensin II type I receptor interaction. Kidney Int 2004; 66: 2137-2147.
79. Cooper ME. Interaction of metabolic and haemodynamic factors in mediating experimental diabetic nephropathy. Diabetologia 2001; 44: 1957-1972.
80. Fukami K, Cooper ME, Forbes JM. Agents in development for the treatment of diabetic nephropathy. Expert Opin Investig Drugs 2005; 14: 279-294.
81. Yamagishi S, Fukami K, Ueda S, Okuda S. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention. Curr Drug Targets 2007; 8: 952-959.
82. Takuwa N, Ohkura S, Takashima S, Ohtani K, Okamoto Y, Tanaka T, et al. S1P3-mediated cardiac fibrosis in sphingosine kinase 1 transgenic mice involves reactive oxygen species. Cardiovasc Res 2010; 85: 484-493.
83. Yamashita H, Kitayama J, Shida D, Yamaguchi H, Mori K, Osada M, et al. Sphingosine 1-phosphate receptor expression profile in human gastric cancer cells: differential regulation on the migration and proliferation. J Surg Res 2006; 130: 80-87.
84. Meyer zu Heringdorf D, Jakobs KH. Renal mesangial cells: moving on sphingosine kinase-1. Br J Pharmacol 2007; 150: 255-257.